Liraglutide Dosage: 0.6 to 3.0mg Weight Loss Schedule

Liraglutide is an FDA-approved GLP-1 receptor agonist with 97% homology to native human GLP-1 — one of the most extensively studied peptide therapies for both type 2 diabetes and weight management. Unlike many peptides on this site, liraglutide has well-established FDA-approved dosing. This is not medical advice — work with your prescriber.

Research-context information only. Liraglutide is the active ingredient in FDA-approved products for type 2 diabetes and chronic weight management; research-peptide and compounded forms are not FDA-approved and are sold for research purposes only. Protocols, doses, and reactions reported below come from clinical trials and community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Quick Reference: Community Protocol

Liraglutide uses FDA-approved dosing as the protocol.

The FDA-approved titration schedule used in clinical trials:

• Week 1: 0.6 mg daily
• Week 2: 1.2 mg daily
• Week 3: 1.8 mg daily
• Week 4: 2.4 mg daily
• Week 5+: 3.0 mg daily

Cycling Details

Liraglutide for weight management was studied as long-term continuous use — no cycling. The 5-week titration was central to the trial protocol: each 0.6 mg increment allows GLP-1 receptors in the GI tract to adapt, substantially reducing nausea and vomiting.

When 3.0 mg was not tolerated, trial protocols maintained the highest tolerated dose. When nausea was severe at a given step, protocols described holding the current dose for an extra week before increasing. Weight regain typically occurred upon discontinuation — the SCALE trial ran 56 weeks with continued benefit.

Missed dose: Product labeling describes injecting as usual if less than 12 hours late; if more than 12 hours, skipping and resuming the next day. Double dosing is not described in any protocol.

Lyophilized Vial Reconstitution (Research Use)

For compounding pharmacies or research-grade liraglutide in lyophilized form:

The dilution math underlying published reconstitution protocols: 5,000 mcg ÷ 2 mL = 2,500 mcg/mL. At a 600 mcg target dose, community-documented draw volumes work out to 0.24 mL (24 units on a standard insulin syringe). Higher target doses favor a 10 mg vial with 2 mL BAC water (5 mg/mL).

Research facilities and compounding pharmacies sourcing bacteriostatic water for peptide reconstitution commonly use the following suppliers.

Routes of Administration

Subcutaneous (only approved route): Abdomen (most common, best absorption), thigh, or upper arm. Protocols describe rotating sites within the same region, pinching a skin fold, inserting at a 90-degree angle, and holding 6 seconds before withdrawing.

Pre-filled pen use: Product labeling describes a new needle for each injection and priming before first use (dial 0.6 mg, point up, press until a drop appears). No reconstitution needed.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

Liraglutide has one of the strongest clinical evidence bases of any peptide therapy.

The landmark SCALE trial (3,731 patients, 56 weeks) showed 8.0% average weight loss with liraglutide 3.0 mg vs 2.6% with placebo. 63.2% of patients lost 5%+ body weight (Pi-Sunyer et al., 2015). The SCALE Diabetes trial (846 patients with T2D) showed 6.0% weight loss with significant HbA1c improvement (Davies et al., 2015).

The LEADER cardiovascular outcomes trial (9,340 patients, 3.8 years) demonstrated a 13% reduction in major adverse cardiovascular events and 22% reduction in cardiovascular death (Marso et al., 2016). A comprehensive review confirmed efficacy across multiple populations and the importance of the titration schedule (Mehta et al., 2017).

Where to Source

Ready to buy? Compare verified vendors on our best liraglutide sources page, or browse all coupon codes for up to 50% off. (Affiliate links — we earn a commission at no cost to you.)

Stacking Protocols

Combining with other GLP-1 RAs (semaglutide, tirzepatide) is described as redundant — overlapping mechanisms and increased GI side effects. Trial data describes sulfonylurea dose reduction (hypoglycemia risk) and careful insulin adjustment when co-administered.

For comparisons with other GLP-1 agents, see our liraglutide vs semaglutide comparison.

Side Effects & Safety

• Nausea — 39% (most common, peaks during dose escalation, improves after 4-8 weeks)
• Diarrhea — 21%
• Constipation — 19%
• Vomiting — 16%
• Headache — 14%
• Pancreatitis — rare (<0.5%); trials flagged it for immediate discontinuation and evaluation
• Gallbladder disease — increased with rapid weight loss
• Thyroid C-cell tumors — boxed warning based on rodent studies; contraindicated with MTC/MEN2 history

GI side-effect management reported in trials and community sources: slow titration (most effective in trial data), smaller meals, hydration, avoiding high-fat meals, and holding any dose step for an extra week when needed.

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). FDA-approved liraglutide ships in a pre-filled pen and requires no syringe math — the pen dial selects the dose in mg directly. The conversions below apply only to research-grade compounded liraglutide reconstituted from a lyophilized vial.

Liraglutide is dosed daily, and target doses (1.2-3.0 mg) sit at the high end of what an insulin syringe can hold per injection, so the chosen dilution matters.

Reconstitution A: 5 mg vial + 2 mL BAC water (2.5 mg/mL) — practical for low-titration steps; high doses approach the 100-unit syringe limit and may require splitting into two draws.

Reconstitution B: 10 mg vial + 2 mL BAC water (5 mg/mL) — half the units per dose; the practical option for the 3.0 mg weight-management target.

These conversions reflect the dilutions documented in published reconstitution protocols and community sources. They report how reconstitution math is described, not a recommended dosing schedule.